Dendritic cells have the ability to efficiently present internalized antigens on major
histocompatibility complex (MHC) I molecules. This process is termed cross-presentation …

The presentation of exogenous antigens on MHC class I molecules, known as cross-
presentation, is essential for the initiation of CD8+ T cell responses. In vivo, cross …

During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …

Dendritic cells are at the center of immune responses. They are defined by their ability to
sense the environment, take up and process antigen, migrate to secondary lymphoid …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Dendritic cell (DC) targeting is a novel strategy to enhance vaccination efficacy. This
approach is based on the in situ delivery of antigen via antibodies that are specific for …

Despite significant effort, the development of effective vaccines inducing strong and durable
T-cell responses against intracellular pathogens and cancer cells has remained a …

Dendritic cells (DCs) are highly specialized antigen presenting cells of the immune system
which play a key role in regulating immune responses. Depending on the method of antigen …

Dendritic cells (DCs) can capture extracellular antigens and load resultant peptides on to
MHC class I molecules, a process termed cross presentation. The mechanisms of cross …

Human BDCA3+ dendritic cells (DCs), the proposed equivalent to mouse CD8α+ DCs, are
widely thought to cross present antigens on MHC class I (MHCI) molecules more efficiently …